Literature DB >> 3243384

Analysis of cell-differentiation lineage in human teratomas using new monoclonal antibodies to cytostructural antigens of embryonal carcinoma cells.

M F Pera1, M J Blasco-Lafita, S Cooper, M Mason, J Mills, P Monaghan.   

Abstract

Human embryonal carcinoma cells sometimes display the developmental potential of early embryonic stem cells. While available data do not clearly identify a counterpart of these tumor cells in normal development, previous comparisons of human embryonal carcinoma and yolk sac carcinomas indicated that these cell types are closely related, and suggested that embryonal carcinoma cells might resemble the progenitors of extraembryonic endoderm. To analyse further cell-differentiation lineage in these tumors, we produced monoclonal antibodies to cytostructurally associated antigens of human embryonal carcinoma cells. Spleen cells from mice immunized with a detergent-insoluble extract of cultured human embryonal carcinoma cells were fused to NS-1 myeloma cells, and hybridoma supernatants were screened by indirect immunofluorescence on the immunizing cell line, then on a panel of cell lines derived from human embryonal carcinomas, yolk sac carcinomas, and a range of neoplastic and normal tissues. Monoclonal antibody GCTM-1 stained the nuclei of all human cells tested and served as a positive control; this antibody immunoprecipitated proteins of 85 and 66 k Da from human embryonal carcinoma cells. GCTM-2 recognized an epitope on a 200-k Da extracellular protein present on the surface of embryonal carcinoma cells, and stained the surface of visceral yolk sac-type carcinoma and colorectal carcinoma cells as well. Enzymatic analysis of carbohydrate residues on the GCTM-2 antigen revealed that it was a keratan sulphate proteoglycan, and suggested that the epitope recognized by the antibody lies on the core protein. In immunoblots, antibody GCTM-3 bound to a 57-k Da cytoskeletal protein expressed in human embryonal carcinoma. This antibody decorated filamentous arrays in cell lines from human embryonal carcinoma, visceral yolk sac carcinoma, parietal yolk sac carcinoma (endodermal sinus tumour), and adenocarcinoma and large cell carcinoma of the lung. Antibody GCTM-4 recognized a determinant present on a 69-k Da polypeptide, associated with a component of the lysosomal compartment, which was expressed in embryonal carcinoma cells, but no other cell type tested. The results with this antibody panel thus allow distinction between human embryonal carcinoma and yolk sac carcinoma, but provide further evidence of a close relationship between these cell types.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3243384     DOI: 10.1111/j.1432-0436.1988.tb00089.x

Source DB:  PubMed          Journal:  Differentiation        ISSN: 0301-4681            Impact factor:   3.880


  15 in total

1.  Biochemical properties of a keratan sulphate/chondroitin sulphate proteoglycan expressed in primate pluripotent stem cells.

Authors:  Susan Cooper; William Bennett; Jessica Andrade; Benjamin E Reubinoff; James Thomson; Martin F Pera
Journal:  J Anat       Date:  2002-03       Impact factor: 2.610

2.  Pre-clinical activity of taxol in non-seminomatous germ cell tumor cell lines and nude mouse xenografts.

Authors:  T A Dunn; V Grünwald; C Bokemeyer; J Casper
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

3.  Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines.

Authors:  T A Dunn; H J Schmoll; V Grünwald; C Bokemeyer; J Casper
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 4.  Porcine embryonic stem cells: a possible source for cell replacement therapy.

Authors:  Vanessa Hall
Journal:  Stem Cell Rev       Date:  2008-12       Impact factor: 5.739

5.  A Cytotoxic Antibody Recognizing Lacto-N-fucopentaose I (LNFP I) on Human Induced Pluripotent Stem (hiPS) Cells.

Authors:  Shogo Matsumoto; Hiromi Nakao; Keiko Kawabe; Motohiro Nonaka; Hidenao Toyoda; Yuto Takishima; Kenji Kawabata; Tomoko Yamaguchi; Miho K Furue; Takao Taki; Takeshi Okumura; Yuzo Yamazaki; Shuuichi Nakaya; Nobuko Kawasaki; Toshisuke Kawasaki
Journal:  J Biol Chem       Date:  2015-06-22       Impact factor: 5.157

6.  Binding specificity of R-10G and TRA-1-60/81, and substrate specificity of keratanase II studied with chemically synthesized oligosaccharides.

Authors:  Hiromi Nakao; Yuko Nagai; Aya Kojima; Hidenao Toyoda; Nobuko Kawasaki; Toshisuke Kawasaki
Journal:  Glycoconj J       Date:  2017-03-14       Impact factor: 2.916

7.  The binding specificity of the marker antibodies Tra-1-60 and Tra-1-81 reveals a novel pluripotency-associated type 1 lactosamine epitope.

Authors:  Suvi Natunen; Tero Satomaa; Virve Pitkänen; Hanna Salo; Milla Mikkola; Jari Natunen; Timo Otonkoski; Leena Valmu
Journal:  Glycobiology       Date:  2010-12-15       Impact factor: 4.313

8.  A self-renewal program controls the expansion of genetically unstable cancer stem cells in pluripotent stem cell-derived tumors.

Authors:  Anne E Conway; Anne Lindgren; Zoran Galic; April D Pyle; Hong Wu; Jerome A Zack; Matteo Pelligrini; Michael A Teitell; Amander T Clark
Journal:  Stem Cells       Date:  2009-01       Impact factor: 6.277

9.  The Universal 3D3 Antibody of Human PODXL Is Pluripotent Cytotoxic, and Identifies a Residual Population After Extended Differentiation of Pluripotent Stem Cells.

Authors:  Lei Kang; Chunping Yao; Alireza Khodadadi-Jamayran; Weihua Xu; Ruowen Zhang; Nilam Sanjib Banerjee; Chia-Wei Chang; Louise T Chow; Tim Townes; Kejin Hu
Journal:  Stem Cells Dev       Date:  2016-04-01       Impact factor: 3.272

10.  A novel keratan sulphate proteoglycan from a human embryonal carcinoma cell line.

Authors:  S Cooper; M F Pera; W Bennett; J T Finch
Journal:  Biochem J       Date:  1992-09-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.